Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Annexon has added a Month 24 dual primary endpoint to its ongoing Phase 3 ARCHER II trial of vonaprument for geographic atrophy, allowing the trial to succeed at either Month 15 or Month 24. The company also launched an open-label extension study and reported that the trial maintains strong statistical power with high patient compliance (>95%) and a low discontinuation rate (<10%).

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.